Doravirine vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)
Result source: NCT02403674
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
NCT02121795 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
Reported efficacy
Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)
Result source: NCT02842086
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Doravirine | Tenofovir alafenamide/emtricitabine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757803 other results
| 94.3% vs 93%vs FTC/TDFNCT0212179531 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778 | 0.4% vs 1.1%vs DTG + F/TAFNCT031103802 other results
|
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578014 other results
| 60 vs 42vs Baseline Treatment Regimen (SBR)NCT0181573636 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Doravirine
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
3 other results
- 84.3% vs 80.8% NCT02403674
- 73.1% vs 66% NCT02275780
- 77.5% vs 73.6% NCT02403674
- Tenofovir alafenamide/emtricitabine
- 94.3% vs 93%vs FTC/TDFNCT02121795
31 other results
- 88.6% vs 92.4% NCT02469246
- 91.6% vs 88.5% NCT01797445
- 92.4% vs 93% NCT02607930
- 87.2% vs 80.8% NCT01705574
- 93.4% vs 97.8% NCT02605954
- 96.6% vs 97.8% NCT02605954
- 88.6% vs 89.1% NCT02121795
- 82.1% vs 88.4% NCT02469246
- 84% vs 82.3% NCT01797445
- 92.8% vs 89.1% NCT01815736
- 87.9% vs 89.8% NCT02607930
- 81.5% vs 84.1% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 90.4% vs 92% NCT04143594
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 96.9% vs 93.9% NCT02397694
- 88.4% vs 89.7% NCT01497899
- 74.8% vs 74% NCT01565850
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 96.9% vs 90.9% NCT02397694
- 88.4% vs 87.9% NCT01497899
- 76.7% vs 84% NCT01565850
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)
- Doravirine
- 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778
- Tenofovir alafenamide/emtricitabine
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
2 other results
- 1.8% vs 0.7% NCT02469246
- 2.5% vs 1.1% NCT02469246
CD4 count, change (week 48)
- Doravirine
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
14 other results
- 192.7 vs 185.6 NCT02275780
- 217.1 vs 319.9 NCT04233879
- 182.4 vs 233.5 NCT04233879
- 0.5 vs 66.3 NCT04223791
- 5.4 vs 62.7 NCT04223791
- -19.7 vs 40.5 NCT04223791
- 239.6 vs 350.9 NCT04233879
- 259.2 vs 263.6 NCT01632345
- 191.9 vs 194.5 NCT01632345
- 133.6 vs 121.1 NCT01632345
- 152.3 vs 146 NCT01632345
- 140.7 vs 121.1 NCT01632345
- 112.9 vs 121.1 NCT01632345
- 154.1 vs 121.1 NCT01632345
- Tenofovir alafenamide/emtricitabine
- 60 vs 42vs Baseline Treatment Regimen (SBR)NCT01815736
36 other results
- 278 vs 289 NCT02607956
- 299 vs 317 NCT02607930
- 50 vs 46 NCT02121795
- -29 vs 10 NCT02469246
- 274 vs 260 NCT01797445
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 20 vs 21 NCT02121795
- -30 vs 2 NCT02469246
- 225 vs 200 NCT01797445
- 180 vs 201 NCT02607956
- 235 vs 228 NCT02607930
- 18 vs 36 NCT03110380
- 221 vs 212 NCT01705574
- 56 vs -1 NCT02616783
- 5 vs 41 NCT01968551
- 48 vs -4 NCT02616783
- -28 vs 8 NCT02605954
- -23 vs 8 NCT02605954
- 23 vs 12 NCT01968551
- 275 vs 248 NCT04143594
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 177 vs 204 NCT01497899
- 231 vs 212 NCT01565850
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- 165 vs 179 NCT01497899
- 186 vs 139 NCT01565850
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Doravirine: 13 of 13 rows · Tenofovir alafenamide/emtricitabine: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Doravirine Rows use multiple source trials | Tenofovir alafenamide/emtricitabine Rows use multiple source trials |
|---|---|---|
| CD4 percent change · % of baseline No placebo or comparator arm | -0.4% (n=43) @ 48wka,b NCT03332095 · Phase 1/2 · combination | 5.7% (n=35) @ 48wka,b NCT01967940 · Phase 3 · registry result, not featured evidence · combination 2 other source trials-1.1% (n=10) @ 48wk NCT02276612 · Phase 2/3 · registry result, not featured evidence -0.1% (n=48) @ 48wk NCT02276612 · Phase 2/3 · registry result, not featured evidence |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 80.1 cells/uL @ 48wkc,d NCT03332095 · Phase 1/2 · combination | 224 cells/uL @ 48wke,c,d NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 show 2 more doses-66 cells/uL @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 -179 cells/uL @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 |
| CD4+ absolute change · percentage points No placebo or comparator arm | 4.49% (n=284) @ 96wkf,d,g,h NCT04223778 · Phase 3 · registry result, not featured evidence | 9.3% (n=50) @ 48wke,f,d,g,h NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 show 2 more doses-0.6% (n=52) @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0.2% (n=27) @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 |
| Hip BMD percent change · % of baseline Maintenance | 0.6% (n=35) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mge,i,j,g NCT04636437 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-0.81% (n=40) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination | -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wki,j,g NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1 other source trial1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk NCT02616783 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Induction | -1.23 vs 0.03 placebo log @ 1wke,k,b,l NCT04233216 · Phase 3 · registry result, not featured evidence · combination show 1 more dose-1.23 vs -0.44 ISL log @ 1wk NCT04233216 · Phase 3 · registry result, not featured evidence · combination | -3.03 vs -3.15 DTG + F/TAF log @ 12wkk,b,l NCT02397694 · Phase 2 · registry result, not featured evidence · combination |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.1 log @ 48wka,b NCT03332095 · Phase 1/2 · combination | -3.04 log @ 48wka,b NCT01967940 · Phase 3 · registry result, not featured evidence · combination |
| HIV-1 RNA 0.5 log10 Decrease responder rate · % of participants Induction | 85.7% (n=7) vs 0% (n=7) placebo @ 1wke,b,g,m NCT04233216 · Phase 3 · registry result, not featured evidence · combination show 1 more dose85.7% (n=7) vs 28.6% (n=7) ISL @ 1wk NCT04233216 · Phase 3 · registry result, not featured evidence · combination | 60.7% (n=28) vs 0% (n=15) placebo @ 1.428571wke,b,g,m NCT01967940 · Phase 3 · registry result, not featured evidence show 1 more dose58.3% (n=12) vs 0% (n=15) placebo @ 1.428571wk NCT01967940 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 92.5% (n=40) @ 96wka,b,g NCT03332095 · Phase 1/2 · combination | 88.4% (n=242) @ 96wke,a,b,g NCT01818596 · Phase 3 show 1 more dose100% (n=6) @ 96wk NCT01818596 · Phase 3 |
| Lumbar Spine BMD percent change · % of baseline Maintenance | 0.88% (n=35) vs 0.38% (n=40) INSTI+TAF/FTC @ 48wk100 mge,i,j,g NCT04636437 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.43% (n=42) vs 0.38% (n=40) INSTI+TAF/FTC @ 48wk100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination | 2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wki,j,g NCT02616783 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 24.2%100 mgn NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 19.6%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 10%Cohort 1: DOR NCT03332095 · Phase 1/2 2.2%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 20.4%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 8.2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 0% NCT04689737 · Phase 4 · registry result, not featured evidence 30.4%DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 80.2%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 17%Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 42.9%DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 33.3%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 43.6%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 28.6% NCT04900974 · Phase 1 · registry result, not featured evidence 0% NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 11.4%F/TAF + 3rd Agento NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 23.5%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 20%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 5.1%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 12.6%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 4%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 1.9%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 4.4% NCT04782180 · Phase 4 · registry result, not featured evidence 18.7% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 17.1%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 5.3%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 5.4%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 0%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 9.1%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 3.3%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 8%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 21.2%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 19.4% NCT01565850 · Phase 2 · registry result, not featured evidence 3% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 1.6%100 mgn NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 3%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 —Cohort 1: DOR NCT03332095 · Phase 1/2 —Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination — NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence — NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination —200 mg NCT01466985 · Phase 1 · registry result, not featured evidence —25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 1.5%F/TAF + 3rd Agento NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 4.2%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 0.7%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 0.7%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 2.8%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 —Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 — NCT04782180 · Phase 4 · registry result, not featured evidence 1.2% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 2.7%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence —E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence —Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence —E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 1.9%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence 0% NCT01565850 · Phase 2 · registry result, not featured evidence — NCT03960645 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 11.7%100 mgn NCT02275780 · Phase 3 · combination show 44 more results6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 6%DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 4.5%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 5.2%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 6.3%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 8.2%DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 —MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 0%Cohort 1: DOR NCT03332095 · Phase 1/2 4.4%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 10.6%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 25% NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 4.3%DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 6.2%DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.6%DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.5%DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 6.4%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 5.3%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.1%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 0%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.7%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.8%Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence 4%Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence 3.7%Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 2.7%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 10.2%100 mg NCT01632345 · Phase 2 · registry result, not featured evidence 7.3%200 mg NCT01632345 · Phase 2 · registry result, not featured evidence 2.3%50 mg NCT01632345 · Phase 2 · registry result, not featured evidence 10%25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 0% NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | —F/TAF + 3rd Agento NCT02121795 · Phase 3 · combination show 52 more results8.7%F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination 6.1%Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 9.7%Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 —F/TAF NCT02469246 · Phase 3 19.6%F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 0%Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 0%Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 —E/C/F/TAF NCT01797445 · Phase 3 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 —E/C/F/TAF NCT01815736 · Phase 3 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 22.7%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 16.7%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 20%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 13.5%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 3.7%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0% NCT04782180 · Phase 4 · registry result, not featured evidence 20% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 14%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 4.5%Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 9.5%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 16.2%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 10.7%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 10.8%Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination 16.2%HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence 0%HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 4.8%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 10.1%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 6%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 7.7%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.9% NCT01565850 · Phase 2 · registry result, not featured evidence 18.2% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mgn diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · combination show 33 more resultsnasopharyngitis 13.7% upper respiratory tract infection 7.2% headache 6.2% NCT02403674 · Phase 3 · HIV · phase 3 nasopharyngitis 9.7% upper respiratory tract infection 7.1% diarrhoea 6.3% NCT02403674 · Phase 3 · HIV · phase 3 aspartate aminotransferase increased 22.2% blood alkaline phosphatase increased 11.1% blood glucose increased 11.1% NCT03332095 · Phase 1/2 glomerular filtration rate decreased 55.6% alanine aminotransferase increased 46.7% blood creatinine increased 46.7% NCT03332095 · Phase 1/2 · combination 100 mg creatinine renal clearance decreased 10.6% low density lipoprotein increased 6.4% abdominal pain upper 2.1% NCT04636437 · Phase 4 · registry result, not featured evidence · combination 100 mg creatinine renal clearance decreased 8.2% aspartate aminotransferase increased 4.1% alanine aminotransferase increased 2% NCT04636437 · Phase 4 · registry result, not featured evidence · combination headache 8.1% covid-19 5.9% arthralgia 5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 13.1% lymphocyte count decreased 10.5% cd4 lymphocytes decreased 9.2% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 32.3% cd4 lymphocytes decreased 23.7% covid-19 12.4% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 15.9% cd4 lymphocytes decreased 11.4% covid-19 1.5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 2.6% nasopharyngitis 2% diarrhoea 1% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 100 mg/0.75 mg covid-19 14.1% headache 10.4% lymphocyte count decreased 9.1% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 24.1% cd4 lymphocytes decreased 10.5% covid-19 7.5% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 17.1% cd4 lymphocytes decreased 8.2% upper respiratory tract infection 2.7% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 14.3% accidental overdose 0% arthralgia 0% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg upper respiratory tract infection 6.3% insomnia 1.8% headache 0.9% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 headache 10.7% accidental overdose 7.1% covid-19 5.4% NCT04223778 · Phase 3 · registry result, not featured evidence lymphocyte count decreased 20.2% cd4 lymphocytes decreased 14% covid-19 13% NCT04223778 · Phase 3 · registry result, not featured evidence covid-19 17.5% lymphocyte count decreased 13.5% cd4 lymphocytes decreased 12% NCT04223778 · Phase 3 · registry result, not featured evidence blood creatine phosphokinase increased 28.6% (placebo 14.3%) diarrhoea 28.6% (placebo 14.3%) anaemia 14.3% (placebo 0%) NCT04233216 · Phase 3 · registry result, not featured evidence · combination dizziness 33.3% dyspepsia 33.3% headache 33.3% NCT04295772 · Phase 2 · registry result, not featured evidence covid-19 100% adjustment disorder 0% back pain 0% NCT04295772 · Phase 2 · registry result, not featured evidence oropharyngeal pain 10.8% cough 8.1% nasal congestion 8.1% NCT04295772 · Phase 2 · registry result, not featured evidence cough 28.6% oropharyngeal pain 21.4% rhinorrhoea 21.4% NCT04295772 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 17.6% diarrhea 14.8% dizziness 14.8% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 29.3% nausea 22% headache 17.1% NCT01632345 · Phase 2 · registry result, not featured evidence 50 mg abnormal dreams 20.9% nausea 16.3% headache 14% NCT01632345 · Phase 2 · registry result, not featured evidence 25 mg diarrhea 25% fatigue 17.5% influenza 15% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 33.3%) abdominal pain 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence 25 mg alanine aminotransferase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 0%) decreased appetite 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence | o upper respiratory tract infection 16.2% diarrhoea 13.2% nasopharyngitis 12.9% NCT02121795 · Phase 3 · combination show 45 more resultsupper respiratory tract infection 40% respiratory tract infection 38% nausea 30% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 26.9% vomiting 25% respiratory tract infection 21.2% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 51.9% cough 33.3% nasopharyngitis 18.5% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 diarrhoea 20.6% headache 17.8% nasopharyngitis 15.9% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 syphilis 8.7% covid-19 7.9% nasopharyngitis 7.1% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 nasopharyngitis 15.5% upper respiratory tract infection 11.6% diarrhoea 9.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.2% arthralgia 3.2% bronchitis 3.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 8.6% diarrhoea 6% fatigue 6% NCT03110380 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence arthralgia 9% diarrhoea 4.5% headache 4.5% NCT02605954 · Phase 3 · registry result, not featured evidence diarrhoea 10.4% headache 8.2% vitamin d deficiency 7.1% NCT02605954 · Phase 3 · registry result, not featured evidence urinary tract infection 13.5% upper respiratory tract infection 12.2% arthralgia 9.5% NCT02707601 · Phase 3 · registry result, not featured evidence · combination cough 13.5% headache 10.8% nausea 8.1% NCT02707601 · Phase 3 · registry result, not featured evidence · combination hyperbilirubinaemia 3.6% (placebo 0%) influenza 3.6% (placebo 0%) jaundice 3.6% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence nausea 16.7% (placebo 0%) arthralgia 8.3% (placebo 0%) diarrhoea 8.3% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 29.7% (placebo 0%) malaria 13.5% (placebo 0%) headache 10.8% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 23% nasopharyngitis 12.2% diarrhoea 10.8% NCT02071082 · Phase 3 · registry result, not featured evidence dental caries 33.3% diarrhoea 33.3% herpes zoster 33.3% NCT02071082 · Phase 3 · registry result, not featured evidence acute sinusitis 19% bronchitis 14.3% sinusitis 14.3% NCT01968551 · Phase 3 · registry result, not featured evidence · combination back pain 12.4% upper respiratory tract infection 11.2% bronchitis 6.7% NCT01968551 · Phase 3 · registry result, not featured evidence · combination cough 24% upper respiratory tract infection 22% vomiting 16% NCT02276612 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 60% cough 50% nasal obstruction 30% NCT02276612 · Phase 2/3 · registry result, not featured evidence injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · registry result, not featured evidence · combination injection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · registry result, not featured evidence · combination covid-19 21.2% influenza 21.2% headache 17.3% NCT04143594 · Phase 2 · registry result, not featured evidence · combination diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 21.4% upper respiratory tract infection 15.5% fatigue 13.6% NCT01565850 · Phase 2 · registry result, not featured evidence back pain 12.1% gestational diabetes 12.1% anaemia 9.1% NCT03960645 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 1/2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTrial phases differ: Phase 1/2 versus Phase 2/3.
- dPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 3 versus Phase 2/3.
- gTreatment context has not been resolved for both arms.
- hAssessment timepoints differ: 96 weeks versus 48 weeks.
- iTrial phases differ: Phase 4 versus Phase 3.
- jPopulation context differs: registered conditions differ.
- kTrial phases differ: Phase 3 versus Phase 2.
- lAssessment timepoints differ: 1 weeks versus 12 weeks.
- mAssessment timepoints differ: 1 weeks versus 1.428571 weeks.
- nPopulation comparability has not been reviewed for 24 of these studies.
- oPopulation comparability has not been reviewed for 47 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Doravirine
show 3 more results
show 3 more results
+ 30 further endpoints in the CSV export.
Tenofovir alafenamide/emtricitabine
show 6 more results
show 9 more results
show 1 more result
show 2 more results
show 5 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Tenofovir alafenamide/emtricitabine's landscape